Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap Up on Strong Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX)’s stock price gapped up before the market opened on Tuesday following a better than expected earnings announcement. The stock had previously closed at $145.35, but opened at $159.00. Neurocrine Biosciences shares last traded at $165.2390, with a volume of 749,745 shares.

The company reported $3.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $1.38. Neurocrine Biosciences had a return on equity of 22.43% and a net margin of 20.91%. The firm had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.04 billion. During the same period last year, the company earned $2.04 EPS. The firm’s quarterly revenue was up 41.3% on a year-over-year basis.

Key Stories Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Strong third-quarter performance: Neurocrine reported adjusted earnings of $3.29 per share, well above estimates ranging from $1.91 to $2.67 and up from $2.04 a year earlier. Revenue rose 41.3% year over year to $1.12 billion, exceeding the approximately $1.04 billion consensus. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Product sales surpassed $1 billion: Management said quarterly net product sales exceeded $1 billion for the first time, reflecting strong demand across its portfolio. The company also raised 2026 net sales guidance for INGREZZA to $2.9 billion-$2.925 billion, reinforcing expectations for continued commercial momentum. Neurocrine Biosciences Crosses $1 Billion in Quarterly Product Sales
• Positive Sentiment: Analysts raised targets: Canaccord Genuity increased its target from $210 to $220 and assigned a “buy” rating, while Piper Sandler raised its target from $210 to $215 and maintained an “overweight” rating. Both targets imply substantial appreciation from the referenced $145.35 share price. Canaccord Genuity Group Recommendations Piper Sandler Recommendations
• Neutral Sentiment: Investor focus is likely to remain on management’s earnings-call commentary regarding demand trends, guidance and the company’s broader product pipeline. No material negative development was reported in the supplied coverage. Neurocrine Q3 2026 Earnings Call Transcript

Analyst Upgrades and Downgrades

NBIX has been the topic of several recent analyst reports. BMO Capital Markets cut their price objective on shares of Neurocrine Biosciences from $164.00 to $150.00 and set a “market perform” rating on the stock in a report on Monday, October 12th. Cantor Fitzgerald upped their price target on shares of Neurocrine Biosciences from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Weiss Ratings raised shares of Neurocrine Biosciences from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 14th. Wells Fargo & Company increased their price target on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Finally, Stifel Nicolaus lifted their price target on shares of Neurocrine Biosciences from $188.00 to $215.00 and gave the company a “buy” rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $201.45.

Insider Activity

In other news, insider David Boyer sold 826 shares of the firm’s stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $157.45, for a total value of $130,053.70. Following the transaction, the insider directly owned 8,722 shares in the company, valued at $1,373,278.90. This trade represents a 8.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Matt Abernethy sold 2,311 shares of the firm’s stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $157.20, for a total value of $363,289.20. Following the completion of the transaction, the chief financial officer owned 42,808 shares in the company, valued at approximately $6,729,417.60. This trade represents a 5.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of NBIX. Privium Fund Management B.V. purchased a new position in Neurocrine Biosciences in the third quarter valued at about $3,716,000. Alps Advisors Inc. acquired a new stake in Neurocrine Biosciences during the 3rd quarter valued at approximately $523,000. Heritage Family Offices LLP purchased a new stake in Neurocrine Biosciences during the 3rd quarter worth approximately $84,000. REAP Financial Group LLC purchased a new stake in Neurocrine Biosciences during the 3rd quarter worth approximately $49,000. Finally, Provenance Wealth Advisors LLC purchased a new stake in Neurocrine Biosciences during the 3rd quarter worth approximately $412,000. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Trading Up 14.5%

The stock has a 50-day simple moving average of $146.49 and a 200-day simple moving average of $147.45. The company has a market capitalization of $16.91 billion, a price-to-earnings ratio of 24.36, a price-to-earnings-growth ratio of 0.64 and a beta of 0.36.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.